Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TUBB4A | P04350 | 2/20 | 0.53 |
| ▸ | TUBB | P07437 | 2/20 | 0.53 |
| ▸ | TUBA3C | P0DPH7 | 2/20 | 0.53 |
| ▸ | TUBA1B | P68363 | 2/20 | 0.53 |
| ▸ | TUBA4A | P68366 | 2/20 | 0.53 |
| ▸ | TUBB4B | P68371 | 2/20 | 0.53 |
| ▸ | TUBB3 | Q13509 | 2/20 | 0.53 |
| ▸ | TUBB2A | Q13885 | 2/20 | 0.53 |
| ▸ | TUBB8 | Q3ZCM7 | 2/20 | 0.53 |
| ▸ | TUBA3E | Q6PEY2 | 2/20 | 0.53 |
| ▸ | TUBA1A | Q71U36 | 2/20 | 0.53 |
| ▸ | TUBA1C | Q9BQE3 | 2/20 | 0.53 |
| ▸ | TUBB6 | Q9BUF5 | 2/20 | 0.53 |
| ▸ | TUBB2B | Q9BVA1 | 2/20 | 0.53 |
| ▸ | TUBB1 | Q9H4B7 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24199012 | 0.89 | TUBB4A (0.51) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL10097806 | 0.87 | TUBB4A (0.49) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL12895622 | 0.86 | TUBB4A (0.49) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL11940019 | 0.86 | TUBB4A (0.41) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL16273975 | 0.82 | TUBB4A (0.62) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL10097765 | 0.81 | TUBB4A (0.72) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL10097785 | 0.81 | TUBB4A (0.72) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL12883916 | 0.74 | TUBB4A (0.38) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL12883969 | 0.74 | TUBB4A (0.38) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL10097754 | 0.72 | TUBB4A (0.83) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8501968-B2 | Antitumoral dihydropyran-2-one compounds | PHARMAMAR, S.A. (ES) | 2013-08-06 | — | — | US | disclosed |
| US-8324406-B2 | Antitumoral dihydropyran-2-one compounds | PHARMA MAR, S.A. (ES) | 2012-12-04 | — | — | US | disclosed |
| US-8324406-B2 | Antitumoral dihydropyran-2-one compounds | PHARMA MAR, S.A. (ES) | 2012-12-04 | — | — | US | disclosed |
| US-20120190870-A1 | ANTITUMORAL DIHYDROPYRAN-2-ONE COMPOUNDS | MARTIN LOPEZ MA JESUS (ES) | 2012-07-26 | — | — | US | disclosed |
| EP-2032551-B9 | ANTITUMORAL DIHYDROPYRAN-2-ONE COMPOUNDS | PHARMA MAR SA (ES) | 2012-02-29 | — | — | EP | disclosed |
| EP-2404913-A2 | Process and intermediates for the preparation of antitumoral dihydropyran-2-one compounds | Pharma Mar S.A. (ES) | 2012-01-11 | — | — | EP | disclosed |
| EP-2404912-A2 | Process and intermediates for the preparation of antitumoral dihydropyran-2-one compounds | Pharma Mar S.A. (ES) | 2012-01-11 | — | — | EP | disclosed |
| EP-2032551-B1 | ANTITUMORAL DIHYDROPYRAN-2-ONE COMPOUNDS | PHARMA MAR SA (ES) | 2011-08-31 | — | — | EP | disclosed |
| US-20100048690-A2 | ANTITUMORAL DIHYDROPYRAN-2-ONE COMPOUNDS | PHARMA MAR, S.A. (ES) | 2010-02-25 | — | — | US | disclosed |
| US-20100048690-A2 | ANTITUMORAL DIHYDROPYRAN-2-ONE COMPOUNDS | PHARMA MAR, S.A. (ES) | 2010-02-25 | — | — | US | disclosed |
| US-20090186938-A1 | ANTITUMORAL DIHYDROPYRAN-2-ONE COMPOUNDS | PHARMA MAR, S.A. (ES) | 2009-07-23 | — | — | US | disclosed |
| US-20090186938-A1 | ANTITUMORAL DIHYDROPYRAN-2-ONE COMPOUNDS | PHARMA MAR, S.A. (ES) | 2009-07-23 | — | — | US | disclosed |
| WO-2007144423-A1 | ANTITUMORAL DIHYDROPYRAN-2-ONE COMPOUNDS | PHARMA MAR, S.A. (ES) | 2007-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048690-A2 | ANTITUMORAL DIHYDROPYRAN-2-ONE COMPOUNDS | RPLP1, PKD1, KRAS | TUBB4A 645/4885TUBB 1650/4885TUBA3C 1715/4885 |
| US-20090186938-A1 | ANTITUMORAL DIHYDROPYRAN-2-ONE COMPOUNDS | RPLP1, PKD1, KRAS | TUBB4A 645/4885TUBB 1650/4885TUBA3C 1715/4885 |
| US-20120190870-A1 | ANTITUMORAL DIHYDROPYRAN-2-ONE COMPOUNDS | RPLP1, PKD1, KRAS | TUBB4A 645/4885TUBB 1650/4885TUBA3C 1715/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.